





# Supplementary Information




**Supplementary Figure 1. Scheme illustrating the replacement of IgH hypervariable region (HVR) fragments in DLBCL cells and the associated flow cytometry gating strategy.** Complementary DNA encoding a fluorescent protein (GFP for IgH), followed by sequences for a 2A peptide (which creates a break during translation), a signal peptide, and either an OVA-specific HVR or an endogenous HVR, was knocked in at the start of the immunoglobulin heavy (IgH) translation site using CRISPR-Cas9 methodology. The design for replacing the IgL HVR is similar, utilizing a CFP variant (mTurquoise2) with no D segment. Five days post-electroporation, GFP and mTurquoise2 double-positive cells were sorted for further experiments.





**Supplementary Figure 2.** Schematic presentation of experimental setup for the identification of autoantigen-dependent signaling using dual HVR-replaced DLBCL models and the PamGene platform. This fluorescent platform measures the ability of active kinases in a specimen to phosphorylate specific peptides imprinted on multiplex chip arrays. Each chip contains four arrays, with the STK and PTK arrays displaying 144 serine/threonine and 196 tyrosine immobilized peptides, respectively. Each peptide represents a 15-amino-acid sequence from putative phosphorylation sites in human proteins, derived from the literature and correlated with one or more upstream kinases. In the presence of ATP, the kinases in the sample actively phosphorylate substrates on the PamChip. Phosphorylation is detected using an antibody, while a second FITC-conjugated antibody quantifies the signal.

**A****B**


**Supplementary Figure 3.** CRISPR screen in DLBCL cell lines. (A) CRISPR scores for DNM1/2/3 in DLBCL cell lines, utilizing datasets from Phelan et al. (2018) for the left panel and Reddy et al. (2017) for the right panel. (B) Ranked list of CRISPR scores for the 19,032 genes targeted in the screen. Genes targeted by currently used inhibitors are highlighted in yellow, with DNM2 shown in red (data from Reddy et al., 2017). A CRISPR score < 0 indicates that CRISPR-mediated gene depletion is lethal.




**Supplementary Figure 4. Expression of DNM2mut inhibits transferrin receptor internalization in DLBCL cells.** To induce DNM2 wild-type (DNM2wt) or mutant (DNM2mut) versions, U2932 cells were incubated with doxycycline (DOX) (100 ng/mL) for 24 hours. Flow cytometry-based transferrin assays were then performed, and results are presented as histograms and MFI plots (means  $\pm$  SD of 2 independent replicates). Transferrin-AF488 internalization in cells expressing DNM2wt is not impaired, therefore most of the transferrin-AF488 is located inside the cell. Addition of anti-AF488 quenching antibody, does not significantly affect the signal. In cells expressing DNM2mut, transferrin-AF488 internalization is inhibited. Therefore, most of the transferrin-AF488 is located on the cell surface, and addition of anti-AF488 antibody significantly inhibits the AF488 signal.



**Supplementary Figure 5.** Phenthiazine derivatives inhibit transferrin receptor internalization in DLBCL cells. U2932 cells were incubated with DMSO, prochlorperazine (PCH) (10 and 15  $\mu$ M), or chlorpromazine (CPZ) (10 and 20  $\mu$ M) for 16 hours, followed by flow cytometry-based transferrin assays. Results are presented as histograms and MFI plots (mean  $\pm$  SD of 2 independent replicates).



**Supplementary Figure 6.** Western blot analysis demonstrating the expression of Dynamin-2 in DLBCL cell lines. GAPDH was used as a loading control.



**Supplementary Figure 7. Hypothetical modes of BCR signaling in DLBCL.** In the ABC-DLBCL subtype, mutations in CD79A/B disrupt BCR internalization, resulting in two distinct pools of BCRs in cells harboring heterozygous mutations: a completely wild-type BCR capable of autoantigen-induced internalization, leading to the assembly of the oncogenic BCR-TLR9 complex, and a BCR with mutated CD79A/B that remains on the cell surface, sustaining tonic BCR signaling. In ABC-DLBCL cells with wild-type CD79A/B, all BCRs can respond to autoantigens; thus, BCR signaling is predominantly reliant on internalization and the assembly of the BCR-TLR9 complex. In contrast, autoantigen-independent (GCB-type) cells primarily utilize tonic BCR signaling, with PI3K (phosphatidylinositol 3-kinase) serving as the major effector.

**Supplementary Table 1.** Sequences of genomic target sites used for knock-in (KI) experiments.

Name	Target Sequence (5' to 3')	Location
HBL1_HV_07	GAAGTGCTTTCTGAGAGTCATGG	V 5' UTR
HBL1_HV_04	AAACCAGGAGAGACGTTGTGAGG	beginning of post J intron
HBL1_LV_01	TGGAGAAGAGCTGCTCAGTTAGG	V 5' UTR
HBL1_LV_04	TCGTGAGATTTTAGTGCCATTGG	beginning of post J intron
Ly19_HV_08	CAGAGGACTCACCATGAAGTTGG	beginning of V
Ly19_HV_06	AAAGTAAATGAGACGTTGTGAGG	beginning of post J intron
Ly19_LV_01	AGAGATTTTCCCTGAAGTTCCGG	V intron
Ly19_LV_03	ATATATCACTTCATAGACACAGG	beginning of post J intron
U2932_HV_02	GCAAGAAAATGAAGCACCTGTGG	beginning of V
U2932_HV_03	AAAGCAGGAGAGAGGTCGTGAGG	beginning of post J intron
U2932_LV_01	TGGAGAAGAGCTGCTCAGTTAGG	V 5' UTR
U2932_LV_04	TAGATCACTTCATAGACACAGGG	beginning of post J intron

**Supplementary Table 2.** Basic characteristics of DLBCL cell lines used.

Cell line	Ig Heavy isotype	Ig light isotype
HBL1	M	K
U2932	M	K
OCI-Ly19	M	K

**Supplementary Table 3.** Neon electroporation conditions.

Cell line	Electroporation conditions
HBL1	1200 V, 20 ms, 2 Pulses, R buffer
U2932	1400 V, 20 ms, 1 Pulse, R buffer
OCI-Ly19	1500 V, 10 ms, 3 Pulses, R buffer

**Supplementary Table 4.** Primers used in gene expression analysis.

<b>TNAIFP3_For</b>	5'-ATGATACTCGGAAGTGAATG-3'
<b>TNAIFP3_Rev</b>	5' - ATGACAATGATTGGCCTTCTG-3'
<b>BCL2L1_For</b>	5' - GGATTTGAATCTCTTCTCTCC-3'
<b>BCL2L1_Rev</b>	5' - CAACCACCAGCTCCCGGT- 3'
<b>CD40_For</b>	5'- AACAGGCAGGCACAAACAAGACTG-3'
<b>CD40_Rev</b>	5'- TGGCAAACAGGATCCCGAAGATGA-3'
<b>BCL2A1-For</b>	5' - CAGAAGATGACAGACTGTGAA-3'
<b>BCL2A1-Rev</b>	5' - TCCAAGCATGACTTCAGATTC-3'
<b>NFkBiz_For</b>	5' - ATGGTGACACGTTCCCTTCATA- 3'
<b>NFkBiz_Rev</b>	5' - CTGCACAATGAGATGCTGATT- 3'
<b>GAPDH_For</b>	5' - AGCCTCCCGCTTCGCTCTCT-3'
<b>GAPDH_Rev</b>	5' - CGACCAAATCCGTTGACTCCGAC-3'



**Supplementary Table 5.** Antibodies used.

<b>Antigen</b>	<b>Source</b>	<b>Catalog no.</b>	<b>Application</b>
Anti-Human Kappa-APC	Thermo Fisher Scientific	MH10515	Flow cytometry
Anti-Mouse CD8a-PE	BD Pharmingen	553032	Flow cytometry
Mouse IgG3-APC	R&D systems	IC007A	Flow cytometry
Rat IgG2A- PE	R&D systems	IC006P	Flow cytometry
<b>4G10 Platinum Anti-Phospho tyrosine</b>	Millipore	05-1050	Western Blot
Anti phospho-IkBa (S32)	Cell Signaling	2859S	Western Blot/PLA
Anti phospho-CD79A (Y182)	Cell Signaling	5173	Western Blot
<b>Anti phospho-SRC family (Y416)</b>	Cell Signaling	2101	Western Blot
Anti phospho-AKT (S473)	Cell Signaling	9271	Western Blot
Anti-Dynamin-2	Abcam	AB65556	Western Blot
Anti-GAPDH	Millipore	MAB 374	Western Blot
<b>Goat Anti-Human IgM, Fc<sub>5μ</sub> fragment specific</b>	Jackson Immunoresearch	109-005-129	PLA
anti-LAMP1	Santa Cruz Biotechnology	sc-20011	PLA
Anti-TLR9	Cell Signaling	2254S	PLA

**Supplementary File 1.** Comparison of tyrosine and serine/threonine kinase activities in HBL1 OVA-specific vs. HBL1 control cells using the chip-based phosphoproteomic PamGene platform.

**Supplementary File 2.** Comparison of tyrosine and serine/threonine kinase activities in K44A-DNM2 mutant vs. wild-type DNM2-expressing HBL1 cells using the chip-based phosphoproteomic PamGene platform.

## SEQUENCES

### Homology arms for H-HVR replacement with inserted GFP and F2A sequences

Sequences of homology arms with inserted GFP and F2A sequences were previously published by Havranek et al. Blood 2017.

Fragments of DNA were inserted into the pSC-B-amp/kan plasmid (Agilent Technologies) and used for ligation mediated assembly of repair template plasmids for H-HVR and L-HVR replacement.

#### The sequences are marked as follows:

Introns: GTTATAT

Exons in bold: **CCTTAAA**

GFP: **ATGGTGA**

F2A: **GTGACAG**

Splice donor and acceptor sites: **GT AG**

Silent changes to prevent re-targeting of repair template plasmid and modified genomic locus: **ACTGG**

BsmBI restriction cassette: GGAGACGCCCTCGTCTCC

BsmBI restriction sites: GAGACG and CGTCTC

Cas9/sgRNA sites: underlined

#### HBL-1\_H\_HA\_GFP\_F2A

AACTGTATTCCAAAATCTGTCTTTGATCCATGATCACACTTGTCTCCCAGACCAGCTCCTTCAGCACA  
TTTCCCTACCTGGAAGAAGAGGACTCTGGGTTTGGTGAGGGGAGGCCACAGGAAGAGAAGTGGAGTTCTC  
AGAGGGCACAGCCAGCATAACCTCCAGGGTGAGCCCAAAGACTGGGGCCTCCCTCATCCCTTTTT  
ACCTATCCATACAAAGGCACCACCCACATGCAAATCCTCACTTAGGCACCCACAGGAAATGACTACAC  
ATTTCTTAAATTCAGGGTCCAGCTCACATGGGAAGTGCTTTCTGAGAGTCTGAAACTCTGACACAA  
GAAC**ATGGTGAGCAAGGGCGAGGAGCTGTTACCGGGGTGGTGCCATCCTGGTCGAGCTGGACGGCG**  
**ACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACC**  
**CTGAAGTTCATCTGCACCACCGCAAGCTGCCCGTGCCCTGGCCACCCTCGTGACCACCTTCACCTA**  
**CGGCGTGCAGTGTCTCGCCCGCTACCCGACCACATGAAGCAGCAGACTTCTTCAAGTCCGCCATGC**  
**CCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAG**  
**GTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGG**  
**CAACATCCTGGGGACAAGCTGGAGTACAACATAACAGCCACAAGGTCTATATCACCGCCGACAAGC**  
**AGAAGAACGGCATCAAGGTGAACTTCAAGACCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCC**  
**GACCACTACCAGCAGAACACCCCATCGGCGACGGCCCCGTGCTGCTGCCCCGACAACCACTACCTGAG**  
**CACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGTTCGTGA**  
**CCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAG**GTGACAGAGTTGCTGTACAGGATGAAG  
CGGGCCGAGACCTACTGTCCAAGGCCTCTGCTGGCAATTCACCCAACGGAGGCTCGGCATAAGCAAAA  
GATTGTGGCCCCTGTCAAGCAGACTCTGAACTTCGATTTGCTCAAACCTGGCCGGCGATGTGGAGTCCA  
ATCCGGGACCCGGAGACGCCCTCGTCTCCAGGTGAGTCTCTGAGAACGTCTCTCCTGGTTTAACTCTGA  
**CGG**TTTTATTGTATTATTGGGGGAAGTTCGGGTGTTGGGTCTCCTGCCAGGAGAACCCCGGAGCAG  
TCTGGGTGACTCAAGAGGATGCCCTGAGGCAACCGCACCACACAGACGAGGGGCAAGGGCTCCAGAT  
GTTCCCTCCTCCTGAGCCCAACAATACTAATCTCTGTGGCCAGGGCCACCCTAGGCCTCTGGGGTC  
CAATGCCCCACAATCCCCGGGCCCTCCCCGGACTCAGTCTGAGAGGGTCCCAGGGACGTACGGGGCG  
CCACTTCTTGCCAGGGGTCCTGGCATTGTTGTCACAATGTGACAACCTAGTT

**OCI-Ly19\_H\_HA\_GFP\_F2A**

TTAGTGCAAAGTGTTTATCACAGCACAATTTTCATAATAAGACAGCATATTTTCCAAACGCAATCATTG  
CCAGCAAACCTTCCACAGGGCACCGTCGTCTTATCTGGGTACAGCCTACTCCTCAAGGGTCCCACCCTA  
GAGCTTGTTTTATAGTAGGAGATTTGCAAGTAGGGCCCTCCCTCTACTGATGAAAGCCAACCCAACCC  
TGACCTGCAGCTCTCAGAGAGGTGCCTTAGCCCTGGATTCCAAGGCATTTCCACTTGGTGATCAGCA  
CTGAACACAGAGGACTCACC**ATGGTGAGCAAGGGCGAGGAGCTGTTACCCGGGGTGGTGCCCATCCTG**  
**GTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCAC**  
**CTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGCAAGCTGCCCGTGCCCTGGCCACCCTCG**  
**TGACCACCTTACCTACGGCGTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCAGACTTC**  
**TTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTA**  
**CAAGACCCGCGCCGAGGTGAAGTTCAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGCATCG**  
**ACTTCAAGGAGGACGGCAACATCCTGGGGACAAGCTGGAGTACAACACAACAGCCACAAGGTCTAT**  
**ATCACCGCCGACAAGCAGAAGAACGGCATCAAGGTGAACCTCAAGACCCGCCACAACATCGAGGACGG**  
**CAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCATCGGCGACGGCCCCGTGCTGCTGCCCG**  
**ACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTC**  
**CTGCTGGAGTTCGTGACCGCCCGGGATCACTCTCGGCATGGACGAGCTGTACAAG**GTGACAGAGTT  
GCTGTACAGGATGAAGCGGGCCGAGACCTACTGTCCAAGGCCTCTGCTGGCAATTCACCCAACGGAGG  
CTCGGCATAAGCAAAAGATTGTGGCCCCTGTCAAGCAGACTCTGAACCTCGATTTGCTCAAACCTGGCC  
GGCGATGTGGAGTCCAATCCGGGACCC**GGAGACGCCCTCGTCTCCAG**GTGAGTCT**GACAA**GTCTCA  
TTTACTTTAAGTCTGAAGCCTTTTCTGTATTTTGGGGGGAAATACGGGTGCTGGGTCTCCTGCCTA  
GAGAGCCCCGGATCAGCCTGGGAGGCTCAGGAGGACGCCCTGAGGCAACACCGACCACACGGACGAGG  
GGCAAGGGCTCCAGATGTTTCTTCTCGTGAGCCCAGTAGTGCGGGTTTCTCTGTGGCCAGGGCCACC  
CTAGGCCTCTGGGGTCCAATGTCTAACAACACCCGGGCATATCAAGCTTATCGATACCGTTCGACCTCG  
AGGGGGGGCCCCGGTACCCAGCTTTTGTTC

**U2932\_H\_HA\_GFP\_F2A**

GGGTTGAACAGTACTGACCCTATTCCAAAATCTGTCTTGATCCAGGATCACACTCATCTCTCAGACC  
AGCTCCTTACAGCACATCTCTTTACCTGGAAGAAGAGGACTCTGGGCTTGGAGAGGGGAGGCCCAAGA  
AGAGAACTGAGTCTCAAAGGGCACAGCCAGCATTTCTCCTCCAGGGTGAGCTCAAAGACTGGCGCC  
TCTCTCATCCCTTTTACTGCTCCGTACAAACGCACCACCCCATGCAAATCCTCACTTAGGCGCCCA  
CAGGAAGCCACCACAC**ATTTCTTAAATTCAGGTCCAACTCATAAGGGAAATGCTTTCTGAGAG**CCAT  
**GTATCTCATGTGCAAGAAAATGGTGAGCAAGGGCGAGGAGCTGTTACCCGGGGTGGTGCCCATCCTGG**  
**TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACC**  
**TACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGCAAGCTGCCCGTGCCCTGGCCACCCTCGT**  
**GACCACCTTACCTACGGCGTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCAGACTTCT**  
**TCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTAC**  
**AAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGA**  
**CTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACACAACAGCCACAAGTCTATA**  
**TCACCGCCGACAAGCAGAAGAACGGCATCAAGGTGAACCTCAAGACCCGCCACAACATCGAGGACGGC**  
**AGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCATCGGCGACGGCCCCGTGCTGCTGCCCGA**  
**CAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCC**  
**TGCTGGAGTTCGTGACCGCCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGGTGACAGAGTTG**  
CTGTACAGGATGAAGCGGGCCGAGACCTACTGTCCAAGGCCTCTGCTGGCAATTCACCCAACGGAGGC  
TCGGCATAAGCAAAAGATTGTGGCCCCTGTCAAGCAGACTCTGAACCTCGATTTGCTCAAACCTGGCCG  
GCGATGTGGAGTCCAATCCGGGACCC**GGAGACGCCCTCGTCTCCAG**GTGAGT**ACT**TACGACCTCTCTC  
CTGCTTTAACTCTTAAGGATTTTGTGCAATTTTGGGGGGAAATAAGCGTGCTGGGTCTCCTGCCAAG  
AGAGCTCGGGCTGGGTCTCCTGCCATGAGAGCCCCGGAGCAGCCTGGGGCTCAGGAGGATGCCCTGA  
GGCAACAGCGGCCACACAGACGAGGGGCAAAGGCTCCAGATGTTTCTTCTTCTGAGCCCAGCAGCAC  
GGGTCTCTGTGGCCAGGGCCACCCTGGGCCTCTGGGGTCCAATGTCCAACAACCCCGGGCCCTCC  
CCGGGCTCAGTCTGAGAGGGTCCCAGAGACTTAACGGGGTGCCAGTTCTTGCCTGGGGTCTCTC

## Homology arms for L-HVR replacement with inserted mTurquoise2 and F2A

Sequences of homology arms with inserted mTurquoise2 and F2A sequences were previously published by Havranek et al. Blood 2017.

Fragments of DNA were inserted into the pSC-B-amp/kan plasmid (Agilent Technologies) and used for ligation mediated assembly of repair template plasmids for H-HVR and L-HVR replacement.

### The sequences are marked as follows:

Introns: GTTATAT

Exons in bold: **CCTTAAA**

mTurquoise2: **ATGGTGA**

F2A: **GTGACAG**

Splice donor and acceptor sites: **GT AG**

Silent changes to prevent re-targeting of repair template plasmid and modified genomic locus: **ACTGG**

BsmBI restriction cassette: GGAGACGCCCTCGTCTCC

BsmBI restriction sites: GAGACG and CGTCTC

Cas9/sgRNA sites: underlined

### HBL-1\_L\_HA\_mTruquoise2\_F2A

```
CCATCATGCATTTAGGGAGCTGACTGGGCACAAGTTGGAGCAGAAAGAGAAAAATGAAACCACAGCCT
TCTATTTTGTCTTAACAGACTTGTACCAAACATTCTGTGGCTCAATCTAGGTGATGGTGAGACAAGA
GGACACAGGGGTAAATTCTGTGGCCGCAGGGGAGAAGTTCTACCCTCAGACTGAGCCAACGGCCTTT
TCTGGCCTGATCACCTGGGCATGGGCTGCTGAGAGCAGAAAGGGGAGGCAGATTGTCTCTGCAGCTGC
AAGCCCAGCACCCGCCAGCTGCTTTGCATGTCCCTCCCAGCCGCCCTGCAGTCCAGAGCCCATATC
AATGCCTGGGTCAGAGCTCTGGAGAAGAGCTGCTCGTAGACCAGAGGGAACCATGGTGAGCAAG
GGCGAGGAGCTGTTCCACCGGGGTGGTGCCATCCTGGTCGAGCTGGACGGCGACGTAAAACGGCCACAA
GTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCA
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGTCTGGGGCGTGCAGTGCTTC
GCCCCGTACCCCGACCACATGAAGCAGCAGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCG
ACACCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCAC
AAGCTGGAGTACAACTACTTTAGCGACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAA
GGCAAACTTCAAGATCCGCCACAACATCGAGGACGGCGGCGTGCAGCTCGCCGACCACTACCAGCAGA
ACACCCCATCGGGCAGCGCCCCGTGCTGCTGCCCAGAACCACTACCTGAGCACCCAGTCCAAGCTG
AGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGTTCGTGACCGCCCGCCGGGATCAC
TCTCGGCATGGACGAGCTGTACAAGGTGACAGAGTTGCTGTACAGGATGAAGCGGGCCGAGACCTACT
GTCCAAGGCCTCTGCTGGCAATTCACCCAACGGAGGCTCGGCATAAGCAAAAAGATTGTGGCCCTGTC
AAGCAGACTCTGAACTTTCGATTTGCTCAAACTGGCCGGCGATGTGGAGTCCAATCCGGGACCCGGAGA
CGCCCTCGTCTCCACGTAAGTACATCTGTCTCAATTATTCGTGAGATTTTAGTGTCATGAATCATTT
GTGCAAATTTTGTGATATTTTGGTTGAATAAACCTGGTGACCCAGAAGTAAATAGCAGGACACCAGAA
AATGAACTTAAAAATCTGAGCAAATAGACGAATCATTGGGTTTGAGAGGAGAATAGGATTCATGGGGG
AAATGGGGAAAGAAATAGCTAGATTTTCTCTGAACAAGCAGCCTATCTCGTATGATTGGCTTCAAGAG
AAGTTTTTGTGAGGGGAAAGGGTGAGATCCCTCACTGTGACTCACTTTCGGCGGAGGGACCAAGGTG
GAGATCAAACATAAGTGCACTTTCCTAATGCTTTTTTCTTATAAGGTTTTAAATTTGGAGCATTTTTGT
GTTTTGAGATATTAGCTCAGG
```

**OCI-Ly19\_L\_HA\_mTruquoise2\_F2A**

CCCACCCTCTAAGACTTCATTAGACATTCCCTACGAATGGTTATACTCTCCTGTATACTCCCAATACA  
ACTCTAAAATATATATTATCCATATAGTCCTTAGGTTTGTATTAAAGTTTACTTTTTTCTTCAAAT  
ATCTCTTGTACAAACAGCGGCTCTAGAGAGAAAATACATTCCCTCCAGGCAAATCTATGCTGCGCTGGT  
CTGACCTGGGACCCTGGGGACATTGCCCTGTGCTGAGTTACTAAGATGAGCCAGCCCTGCAGCTGTG  
CTCAGCCTGCCCATGCCCTGCTGATTGATTTGCATGTTCCAGAGCACAGCCTCCTGCCCTGAAGACT  
TTTTTAT**GGGCTGGTCGCACCCTGTGCAGGAGTCAGTCTCAGTCAGGACACAGC**ATGGTGAGCAAGGG  
CGAGGAGCTGTTACCCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGT  
TCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCCTGAAGTTCATCTGCACC  
ACCGCAAGCTGCCCGTGCCCTGGCCACCCTCGTGACCACCCTGTCTGGGGCGTGCAGTGCTTCGC  
CCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGG  
AGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGAC  
ACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACA  
GCTGGAGTACAACACTTTAGCGACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGG  
CCAACCTCAAGATCCGCCACAACATCGAGGACGGCGGCGTGCAGCTCGCCGACCACTACCAGCAGAAC  
ACCCCATCGGCGACGGCCCCGTGCTGCTGCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAG  
CAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGTTCGTGACCGCCGCGGGATCACTC  
TCGGCATGGACGAGCTGTACAAGGTGACAGAGTTGCTGTACAGGATGAAGCGGGCCGAGACCTACTGT  
CCAAGGCCTCTGCTGGCAATTCACCCAACGGAGGCTCGGCATAAGCAAAAGATTGTGGCCCTGTCAA  
GCAGACTCTGAACCTCGATTTGCTCAAACCTGGCCGGCGATGTGGAGTCCAATCCGGGACCCGGAGACG  
CCCTCGTCTCC**ACGT**GAGTGGGATTTACACTTTGTTTCTTCACTTGTCTGTGTCTTTTGTTC**CTGCG**  
**T**ATATGAAGTGATATATAAGGTTAGTCTAGAAGCAGTCTGTGACATCCTTCAGGGAAAAAGGTTGATA  
AGTCTGGAATCAAACCTCGAAAATTGATTACACATTTTTTTTTGAGGAATAATCAACCTTCAGGCATTGG  
GTGAGAATAAGTCGTCTACGTAATAATTTAGAGATGTGCTGGGGAACATAACATGTTCTGGACAGAAC  
CTTGGTCAATTGTCACAAAGGGAATTTTTGCATAGGAGGCAAAGTAAGTGAACCAACGTGTATACAC  
TTTTGGCCAGGGGACCAAGG

**U2932\_L\_HA\_mTruquoise2\_F2A**

CCATCATGCATTTAGGGAGCTGACTGGGCACAAGTTGGAGCAGAAAGAGAAAAATGAAACCACAGCCT  
TCTATTTTGTCTTAACAGACTTGTACCAAACATTTCTGTGGCTCAATCTAGGTGATGGTGAGACAAGA  
GGACACAGGGGTTAAATTTCTGTGGCCGAGGGGAGAAGTTCTACCCTCAGACTGAGCCAACGGCCTTT  
TCTGGCCTGATCACCTGGGCATGGGCTGCTGAGAGCAGAAAGGGGAGGCAGATTGTCTCTGCAGCTGC  
AAGCCCAGCACCCGCCAGCTGCTTTGCATGTCCCTCCCAGCCGCCCTGCAGTCCAG**AGCCCATATC**  
**AATGCC****TGGGT****CAGAGCTCTGGAGAAGAGCTGCTCAGT****CAG****TACCT****TG****GGGA****ACC**ATGGTGAGCAAG  
GGCGAGGAGCTGTTACCCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAA  
GTTTACGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCCTGAAGTTCATCTGCA  
CCACCGCAAGCTGCCCGTGCCCTGGCCACCCTCGTGACCACCCTGTCTGGGGCGTGCAGTGCTTC  
GCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA  
GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCG  
ACACCCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCAC  
AAGCTGGAGTACAACACTTTAGCGACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAA  
GGCCAACCTCAAGATCCGCCACAACATCGAGGACGGCGGCGTGCAGCTCGCCGACCACTACCAGCAGA  
ACACCCCATCGGCGACGGCCCCGTGCTGCTGCCGACAACCACTACCTGAGCACCCAGTCCAAGCTG  
AGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGTTCGTGACCGCCGCGGGATCAC  
TCTCGGCATGGACGAGCTGTACAAGGTGACAGAGTTGCTGTACAGGATGAAGCGGGCCGAGACCTACT  
GTCCAAGGCCTCTGCTGGCAATTCACCCAACGGAGGCTCGGCATAAGCAAAAGATTGTGGCCCTGTCA  
AAGCAGACTCTGAACCTCGATTTGCTCAAACCTGGCCGGCGATGTGGAGTCCAATCCGGGACCCGGAGA  
CGCCCTCGTCTCC**ACGT**GAGTAGAATTTAAAGTTTGCTT**ACT****T**AGTTGTCTGTGTCTTCTGCT**TCGG**  
TGCTATGAAGTGATCTATAAACTGACTCTGCAATCAGCCTCTGATATCCTTCAGGGAAAAAGAAAAAG  
ATAAGTCTGTAGTCAAACCTCGAGAATTGATTGCACATTTTCTTTGAAGAGCAAGCAAGATTCAAGTCAT  
TGGGTGAGAATAACTTGTCTAAGTAATAGCTTCAGAAATGTCTGGGGAACATAACATGTTCTGGACA  
GAGCCTTGGTCAATTGTCAGAAAGGGAGTTTTTGTATAGGAGGGAAGTTAAGAGGAACCAATTGTGTGT  
ACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGTAAGTACTTTTTTCCACTGATTCTTCACTGT  
TGCTA

## Endogenous H-HVR and L-HVR fragments

Sequences of H-HVR and L-HVR were previously published by Havranek et al. Blood 2017.

Fragments of DNA were inserted into the pSC-B-amp/kan plasmid (Agilent Technologies) and used for ligation mediated assembly of repair template plasmids for H-HVR and L-HVR replacement.

### The sequences are marked as follows:

Introns: GTTATAT

Exons in bold: **CCTTAAA**

F2A: GTGACAG

Splice donor and acceptor sites: **GT AG**

Silent changes to prevent re-targeting of repair template plasmid and modified genomic locus: **ACTGC**

BsmBI restriction sites: **GAGACG** and **CGTCTC**

BbsI restriction sites: **GAAGAC** and **GTCTTC**

Cas9/sgrNA sites: underlined

### HBL-1\_H-HVR

GGACACTGA**GAAGACCT**ACCC**AAACACCTGTGGTTCTTCCTCCTCCTGGTGGCAGCTCCCGGAT****GT**GA  
GTGTCTCAGGAATGCGGATATGAAGATATGAGATGCTGCCTCTGATCCCAGGACTCACTGTGGGTTTC  
TCTGTTAC**AG**GGGTCCTGTCCAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGG  
AGACCTGTCCCTCACTTGCCTGTCTATGGTGGGTCCTTCAGTGATTACTACTGGACCTGGATCCGT  
**CAGTCCCAGGAAAGGGGCTGGAGTGGATTGGGAAATCAATCGTAGTGGAAGTACCGACTACAACCC**  
**GTCCCTCAAGAGTCGAGTCACCATATCACTAGACACGTCCAAGAACCAATTCTCCCTGCATCTGACCT**  
**CTGTGACCGCCGCGGACACGGCTCTATATTACTGTGCGGGGGACAAGACTACGGTGACTATGTTAGG**  
**GGGGTAGTGACTACTGGGGCCAGGAAACCTGGTCACCGTCTCCTCAG****GT**GGGTCTTCGACC

### HBL-1\_L-HVR

GGAA**CGTCTCC**ACCC**GACACC****CGCGAGCTTCTCTTCCTCCTGCTACTCTGGCTCCAG**  
**GT**GAGGGGAACATGGGATGGTTTTGCATGTGAGTAAAACCTCTCAAGTCTGTTACCTGGCAACTC  
TGCTCAGTCAATAACAATAATTAAGCTCTGTATAAAGCAATAATTCTGGCTCTTCTGGGAAGACAATG  
GGTTTGATTTAGATTACATGGGTGACTTTTCTGTTTTATTTCCAATCTC**AG**ATACCACCGGAGAAATT  
**GTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCCTCAGGGGAAAGAGCCACCCTCTCCTGCAGGGC**  
**CAGTCAGAGTATTAGCAGCAACTACTTAGCCTGGTTCAGCTGAAAGGTGGCCAGGCTCCAGGCTCC**  
**TCATCTTTGGTGCATCCAACAGGGCCACTGGCATCCAGACAGGTTTCAGTGGCAGTGGGTCTGGGACA**  
**GACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGG**  
**TAGCTCACCGATCACTTTTCGGCCCTGG****CACAAAG****GTGGATATCAAAC****GT**GGAGACGAAACC

### OCI-Ly19\_H-HVR

GGATGT**CGTCTCC**ACCC**AAGTTGGGGCTGTGCTGGGTTTTCTTGTGGTATTTTAGAAG****GT**GATTCA  
TGGAAAACCTAGAGAGATTTAGTGTGTGGATATGAATGAGACAAACAGTGGATATGTGTGGCAGTTT  
CTGATTTTGGTGTCTCTTTGTTG**AG**GTGTCCAGTGTGAAGTTGAGTTGGTGGAGTCTGGGGGAGGG  
**TTGGTACAGCCTGGGGGTCTTGGAGACTCTCCTGTGAAGTCTCTGGATTACCTTCAATACCTATAC**  
**TATGAGCTGGGTCCGCCAGGCTCCAGGTAAGGGCTGGAGTGGGTTTTCAAATATTAGTAGTAGTAGTA**

GTGCCATATACTATGCAGGCTCTGTGAAGGGCCGATTCATCATCTCCAGAGACAATGCCAAAACTCA  
TTATATCTGCAAAATGAACAACCTGAGAGCCGAGGACACGGCTGTCTATTTCTGTGCGCGAGCGTCTTA  
TGATTCGGGGACTTATTTCCACGACTACTGGGGCCAGGGAACCTCGTCACAGTCTCCTCAGCTGGAG  
ACGACC

#### OCI-Ly19\_L-HVR

GGAACGTCTCCACCCGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTCCTGCTACTCTGGCTCCGAGG  
TAAGGATGGAGAACAACACTAGGAATTTACTCAGCCAGTGTACTCAGTACTGATCGAAGCTTCAGGGAAAA  
TCTCTGATAACATGATTAGTAGTAAAAATCTTTGTTTTTATGTTTTCACTTTCAGGTGCCAGATGTGA  
CATCCAGATGACCCAGTCTCCCTCGTCCCTGTCAGCATCTGTAGGAGACAGAGTCACTATCACTTGCC  
GGCAAGTCAGAATATTAGGACCAATTTAAATTGGTATCAACAAAACCAGGGAGGGCCCCAAGGTC  
CTGATCTATGCCGCTTCCAGTTTGCAAAGTGGAGTCCCATCAAGATTCAGTGGCAGTGGATCTGGGAC  
ATATTTCACTCTCACCATTAGCAGTCTGCAGCTGAGGATTTGCAACTTCTATTGTCAACAGACGT  
ACAGTTCGTCTGGACGTTCCGGCCAAGGCACAAAAGTGAAATCAGACCTGGAGACGAAACC

#### U2932\_H-HVR

GGACGAAGACCTACCCAAGCACCTGTGGTTCTTCTCCTGCTGGTGGCGGCTCCAGATCTGAGTGT  
TCTAGGATGCAGACATGGAGATATGGGAGACTGCCTCTGATCCCAGGGCTCACTGTGGGTTTTTCTGT  
TCACAGGGGTCTGTCCAGCTGCAGCTGCAGGAGTCGGGCCAGGACTGGTGAAGCCTTCGGAGACC  
CTGTCCCTCACCTGCAGTGTCTCTCGTGTCTCCATCAGCAGTAGTAATTACTACTGGGGCTGGATCCG  
CCAGCCCCAGGGAAGGGGCTGGAATGGATTGGGAGTACTATTATGGTGGCAGTACCTCCTACAACC  
CGTCCCTCAAGGGTCGAGTCATTATATCCGTAGACACGTCCAAGAACCCTTCTCCCTGAACTGACC  
TCTGTGACCGCCGAGACACGGCTCTATATTACTGTGCGAGAGCGCTGTCTTACTATGATACTGGTGG  
TTTCAGGTACTTCTTGGATTATGGGGCCAGGGAACCTGGTCCAGTCTCCTCAGCTGGTCTTCGAC  
CC

#### U2932\_L-HVR

GGAACGTCTCCACCCGAAACCCAGCGCAGCTTCTTCTCCTGCTACTCTGGCTCCAGCTGAGGG  
GAACATGGGATGGTTTTGCATGTCAGTGAAAACCTCTCAAGTCTGTTACCTGGCAACTCTGCTCAG  
TCAATTCATAAATAAAGCTCAATATAAAGCAATAATTCTGGCTCTTCTGGGGAGACAATGGGTTTGA  
TTTAGATTACATGGGTGACTTTTCTGTTTTATTCCAATCTCAGATACCACCGAGAAATTGTGTTGA  
CGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAG  
AGTGTTAGCAGCAGCTACTTAACTGGTACCAGCAGAAACCTGGCCAGGCTCCAGGCTCCTCATCTA  
TGGTGCCTCAACAGGGCCACTGGCATCCAGACAGGTTTCAAGTGGCAGTGGGTCTGGGACAGACTTCA  
CTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTGTCAGCAGTATCGTAGCTCA  
CCTCCGACGTGGACGTTCCGGCCAAGGGACAAAAGTTCGAGATCAAACCTGGAGACGAAACC

## Ovalbumin (OVA) recognizing HVR fragments

Fragments of DNA were inserted into the pSC-B-amp/kan plasmid (Agilent Technologies) and used for ligation mediated assembly of repair template plasmids for H-HVR and L-HVR replacement.

The sequences are marked as follows:

Introns: GTTATAT

Exons in bold: **CCTTAAA**

F2A: GTGACAG

Published sequence that used to re-create the HVR underlined GGCTGT

Splice donor and acceptor sites: **GT AG**

Changes to disrupt low GC window for better gBlock Synthesis **C**

BsmBI restriction sites: GAGACG and CGTCTC

### OVA-H-HVR

GGAACGTCTCCACCCGGATGGAGCTGTATCATCCTCTTTTTGGTAGCAACAGCTACAGGTAAGGGGCT  
CACAGTAGCAGGCTTGAGATCTGGCAATACACTGGGTGACAATGACATCCACTCTCTCTTTCTCTCC  
ATAGGTGTCCACTCCCAGGTCCAACGCAGCAGCCTGGGGCTGTGTTGGTGAGGCCTGGGGCTCAGT  
GAAGCTGTCCTGTAAGGCTTCTGGCTACATCTTCACCAGTTACTGGATGAATTGGGTGAAACAGAGGC  
CTGGACAAGGCCTTGAATGGATTGGTATGATTGATTGTTTCAGACAGAAAACTCACTACAATCAAATG  
TTCAAAGACAAGGCCACATTGACTGTTGACAAGTCCTCCAATATAGCCTACATTCAGCTCATCAGTCT  
GACATCTGAGGACTCTGCGGTCTATTACTGTTCAAGGGGGAGTAAATACTGGGGCCAAGGACTCTGG  
TCACTGTCTCTTCAGGTGGAGACGAAACC

### OVA-L-HVR

GGAACGTCTCCACCCATGAGTCCTGCCAGTTCCTGTTTCTGTTAGTGCTCTGGATTCCGGGGTAAGGA  
GTTCTGGAATGGGAGGGATGAGAATGGGGATGGAGGGTGATCTCTGGATGCCTATGTGTGCTGTTTAT  
TTGTGGTGGGGCAGGTCATATCTTCTAGGATGTGAGGTTTTGTTACATCCTAATGAGATATTCAGAT  
GGAACAGTAGCTGTACTAAGATCAATATTCTGACATAGATTGGATGGAGTGGTATAGACTCTGATGTT  
TAGAACCTTCAACATTTGTTTTATGACAAGATATTTGATATATCATATCTTTAAATCTGAAAACTGC  
TAGGATCTTACTTGAAAGGAATAGCATTTTCAAGTAAGATTTCAAGTAGATTTTCAAGTAGATTTTCA  
AAAGGTTGCTCAGGACCTTGCACATGATTTTCCACTATTGTATTGTAATTTAGAAACCAACGGTGA  
TGTTGTGATGACCCAGACTCCACTCACTTTGTCGGTTACCATTGGACAACCAGCCTCCATCTCTTGCA  
AGTCAAGTCAGAGCCTCTTAGATAGTGATGGAAAGACATATTTGAATTGGTTGTTACAGAGGCCAGGC  
CAGTCTCAAAGCGCCTAATCTATCTGGTGTCTAAACTGGACTCTGGAGTCCCTGACAGGTTCACTGG  
CAGTGGTCTGGAACGGATTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATTTGGGAGTTTATT  
ATTGCTGGCAAGCTACACATTTTCTCAGACGTTGCGGTGGAGGTACCAAGTTGGAATCAAACCTGGA  
GACGAAACC

## Sequences of murine CD8a (mCD8) protein and truncated mCD8a, fused to 17mer-OVA peptide

mCD8A sequence

ATGGCCTCACCGTTGACCCGCTTTCTGTGCTGAACTGCTGCTGCTGGGTGAGTCGATTATCCTGGGGAGTGGA  
GAAGCTAAGCCACAGGCACCCGAACTCCGAATCTTTCCAAAGAAAATGGACGCCGAACTTGGTCAGAAGGTGGAC  
CTGGTATGTGAAGTGTGGGGTCCGTTTCGCAAGGATGCTCTTGGCTCTTCCAGAACTCCAGCTCCAACTCCC  
CAGCCACCTTCGTTGTCTATATGGCTTCATCCCACAACAAGATAACGTGGGACGAGAAGCTGAATTCGTCGAAA  
CTGTTTTCTGCCATGAGGGACACGAATAATAAGTACGTTCTCACCTGAACAAGTTCAGCAAGGAAAACGAAGGC  
TACTATTTCTGCTCAGTCATCAGCAACTCGGTGATGTACTTCAGTTCGTGCGTGCCAGTCTTCAGAAAAGTGAAC  
TCTACTACTACCAAGCCAGTGTGCGAACTCCCTCACCTGTGCACCTACCGGGACATCTCAGCCCCAGAGACCA  
GAAGATTGTCGGCCCCGTGGCTCAGTGAAGGGGACCGGATTGGACTTCGCCTGTGATATTTACATCTGGGCACCC  
TTGGCCGGAATCTGCGTGGCCCTTCTGCTGTCTTGGATCATCACTCTCATCTGCTACCACAGGAGCCGAAAGCGT  
GTTTGCAAATGTCCAGGCCGCTAGTCAGACAGGAAGGCAAGCCAGACCTTCAGAGAAAATTTGTAA  
Signal peptide, extracellular, transmembrane, and intracellular.

OVA 17-mer

TTCGACAAGTTGCCCGGCTTCGGAGATTCCATCGAAGCCCAGGGGGCAAG

Translated: FDKLPGFGDSIEAQGGK

mCD8a-flag-2xOVA-17-mer



GGAAAGCCTCTGAGGCCACCATGCGCTCACCGTTGACCCGCTTTCTGTGCGCTGAACCTGCTGCTGCTGGGTGA  
 GTCGATTATCCTGGGGAGTGGAGAAGCTAAGCCACAGGCACCCGAACCTCCGA  
 TTCGACAAGTTGCCCGGCT  
 TCGGAGATTCCATCGAAGCCCAGGGGGGCAAGGGAGGAGGCAGCGGTGGTGGAAAGTGGATTTCGACAAGTTGC  
 CCGGCTTCGGAGATTCCATCGAAGCCCAGGGGGGCAAGGATTGTGCGGCCCGTGGCTCAGTGAAGGGACCCGAT  
 TGGACTTCGCCTGTGATATTTACATCTGGGCACCCCTTGGCCGGAATCTGCGTGGCCCTTCTGCTGTCTTGATCA  
 TCACTCTCATCTGCTACCACAGGAGCCGATAAGGCCTGTGAGGCCAACC

SfiI site, Signal peptide, part of extracellular domain, 3x flag, OVA-17-mer, linker, OVA-17-mer, part of extracellular domain, transmembrane domain, part of intracellular domain, STOP, SfiI site.

Translated correctly:

MASPLTRFLSLNLLLLGESIILGSGEAKPQAPELRDYKDDDDKDYKDDDDKDYKDDDDKFDKLPFGFD  
 SIEAQGGKGGGSGGGSGFDKLPFGFDSIEAQGGKDCRPRGSVKGTGLDFACDIYIWAPLAGICVALLL  
 SLIITLICYHRSR\*

## Sequences of wild-type and K44A-mutant DNM2

### dymamin 2 WT

ACCACTTCCTACCCTCGAAAGGCCTCTGAGGCCACCatgggcaaccgcgggatggaagagct  
 gatcccgcctggtcaacaactgcaggacgccttcagctccatcggccagagctgccacctgg  
 acctgccgcagatcgctgtagtgggcgccagagcgcggcaagagctcgggtgctggagaac  
 ttcgtgggcccgggacttcttccccgcggttcaggaatcgtcacccggcggcctctcattct  
 gcagctcatcttctcaaaaacagaacatgccgagtttttgactgcaagtcaaaaagttta  
 cagactttgatgaagtccggcaggagattgaagcagagaccgacaggggtcacggggaccaac  
 aaaggcatctccccagtgcccatcaaccttcgagctactcgccacagtggttgaacttgac  
 cctcatcgacctcccgggtatcaccaagggtgctgtgggcgaccagcctccagacatcgagt  
 accagatcaaggacatgatcctgcagttcatcagccgggagagcagcctcattctggctgtc  
 acgcccgccaacatggacctggccaactccgacgcctcaagctggccaaggaagtcgatcc  
 ccaaggcctacggaccatcgggtgtcatcaccaagcttgacctgatggacgagggcaccgacg  
 ccagggacgtcttgagaaacaagtgtctcccgttgagaagaggctacattggcgtggtgaa  
 cgcagccagaaggatattgagggcaagaaggacatccgtgcagcactggcagctgagaggaa  
 gttcttctctcccaccggcctaccggcacatggccgaccgcatgggcacgccacatctgc  
 agaagacgctgaatcagcaactgaccaaccacatccgggagtcgctgccggccctacgtagc  
 aaactacagagccagctgctgtccctggagaaggaggtggaggagtacaagaactttcggcc  
 cgacgaccccaccgcaaaaccaaagccctgctgcagatgggtccagcagtttgggggtggatt  
 ttgagaagaggatcgagggtcaggagatcaggtggacactctggagctctccgggggcgcc  
 cgaatcaatcgcacatcttccacgagcggttccatttgagctggtgaagatggagtttgacga  
 gaaggacttacgacgggagatcagctatgccattaagaacatccatggagtcaggaccgggc  
 ttttcccccgacttggcattcgaggccattgtgaaaagcagggtcgtcaagctgaaagag  
 ccctgtctgaaatgtgtcgacctggttatccaggagctaataacatagttaggcagtgtagc  
 cagtaagctcagttcctacccccggttgcgagaggagacagagcgaatcgtcaccacttaca  
 tccgggaacgggaggggagaacgaaggaccagattcttctgctgatcgacattgagcagtc  
 tacatcaacacgaacatgaggacttcatcgggtttgccaatgccagcagaggagcagcga  
 gctgaacaagaagagagccatccccaatcaggtgatccgcaggggctggctgacatcaaca

acatcagcctgatgaaaggcggctccaaggagtactggtttgtgctgactgccgagtcactg  
tcctgggtacaaggatgaggaggagaaagagaagaagtacatgctgcctctggacaacctcaa  
gatccgtgatgtggagaagggcttcatgtccaacaagcacgtcttcgccatcttcaacacgg  
agcagagaaacgtctacaaggacctgpcggcagatcgagctggcctgtgactcccaggaagac  
gtggacagctggaaggcctcgttctcctccgagctggcgtctaccccgagaaggaccaggcaga  
aaacgaggatggggcccaggagaacaccttctccatggaccccccaactggagcggcaggtgg  
agaccattcgcaacctgggtggactcatacgtggccatcatcaacaagtccatcccgcgacctc  
atgccaaagaccatcatgcacctcatgatcaacaatacgaaggccttcatccaccacgagct  
gctggcctacctatactcctcggcagaccagagcagcctcatggaggagtccggtgaccagg  
cacagcggcgggacgacatgctgcgcatgtaccatgccctcaaggaggcgtcaacatcatc  
ggtgacatcagcaccagcactgtgtccacgcctgtacccccgcctgtcgatgacacctggct  
ccagagcgcagcagccacagccccactccacagcgcgaccgggtgtccagcatacaccccc  
ctggccggccccagcagtgaggggccccactccaggccccccctgattcctgttcccgtg  
ggggcagcagcctccttctcggcgcccccaatcccaccccggcctggaccccagagcgtggt  
tgccaacagtgacctcttcccagccccgcctcagatcccatctcggccagttcggatcccc  
cagggattccccaggagtgccagcagaagacccccctgctgcgcccagcgggccaccatt  
atccgcccagccgagccatccctgctcgacTA GGCCTGTCAGGCCAAGCTTCCATCGATAG  
ACATGATAAGATACATTGATGAGTTTGGACAAACCACAACAAGAATG

## **dymamin 2 K44A**

ACCACTTCCTACCCTCGAAAGGCCTCTGAGGCCACCAatgggcaaccgcgggatggaagagct  
gatcccgcctgggtcaacaactgcaggacgccttcagctccatcgggccagagctgccacctgg  
acctgccgcagatcgctgtagtgggcggccagagcgcgggcggcagctcgggtgctggagaac  
ttcgtgggcccgggacttcttccccgcggttcaggaatcgtcacccggcggcctctcattct  
gcagctcatcttctcaaaaacagaacatgccgagtttttgactgcaagtcaaaaagttta  
cagactttgatgaagtccggcaggagattgaagcagagaccgacaggggtcacggggaccaac  
aaaggcatctccccagtgcccatcaaccttcgagctctactcgccacacgtgttgaaacttgac  
cctcatcgacctcccgggtatcaccaaggtgcctgtgggcgaccagcctccagacatcgagt  
accagatcaaggacatgatcctgcagttcatcagccgggagagcagcctcattctggctgtc  
acgcccgccaacatggacctggccaactccgacgcctcaagctggccaaggaagtcgatcc  
ccaaggcctacggaccatcgggtgtcatcaccaagcttgacctgatggacgagggcaccgacg  
ccagggacgtcttgagaaacaagtgtctcccgttgagaagaggctacattggcgtgggtgac  
cgcagccagaaggatattgagggcaagaaggacatccgtgcagcactggcagctgagaggaa  
gttcttctctcccacccggcctaccggcacatggccgaccgcatgggcacgccacatctgc  
agaagacgtgaatcagcaactgaccaaccacatccgggagtcgctgcccggccctacgtagc  
aaactacagagccagctgctgtccctggagaaggaggtggaggagtacaagaactttcggcc  
cgacgacccccaccgcaaaaccaaagccctgctgcagatgggtccagcagtttgggggtggatt  
ttgagaagaggatcgagggtcaggagatcaggtggacactctggagctctccgggggccc  
cgaatcaatcgcatcttccacgagcggttccatttgagctgggtgaagatggagtttgacga  
gaaggacttacgacgggagatcagctatgccattaagaacatccatggagtcaggaccgggc  
ttttcaccgccgacttggcattcagaggccattgtgaaaaagcaggtcgtcaagctgaaagag  
ccctgtctgaaatgtgtcgacctgggttatccaggagctaatcaatacagttaggcagtgtag  
cagtaagctcagttcctacccccgggttgcgagaggagacagagcgaatcgtcaccacttaca  
tccgggaacgggaggggagaaacgaaggaccagattcttctgctgatcgacattgagcagtc  
tacatcaacacgaacatgaggacttcatcgggtttgccaatgccagcagaggagcagcga  
gctgaacaagaagagagccatccccaatcaggtgatccgcaggggctggctgacctcaaca

acatcagcctgatgaaaggcggctccaaggagtactggtttgtgctgactgccgagtcactg  
tcctgggtacaaggatgaggaggagaaagagaagaagtacatgctgcctctggacaacctcaa  
gatccgtgatgtggagaagggcttcatgtccaacaagcacgtcttcgccatcttcaacacgg  
agcagagaaaacgtctacaaggacctgcggcagatcgagctggcctgtgactcccaggaagac  
gtggacagctggaaggcctcgttctcctccgagctggcgtctaccccgagaaggaccaggcaga  
aaacgaggatggggcccaggagaacaccttctccatggacccccaaactggagcggcaggtgg  
agaccattcgcaacctggtggactcatacgtggccatcatcaacaagtccatcccgcgacctc  
atgccaaagaccatcatgcacctcatgatcaacaatacgaaggccttcatccaccacgagct  
gctggcctacctatactcctcggcagaccagagcagcctcatggaggagtccggtgaccagg  
cacagcggcgggacgacatgctgcgcatgtaccatgccctcaaggaggcgtcaacatcatc  
ggtgacatcagcaccagcactgtgtccacgcctgtacccccgcctgtcgatgacacctggct  
ccagagcgcagcagccacagccccactccacagcgcggaccgggtgtccagcatacaccccc  
ctggccggccccccagcagtgaggggccccactccaggccccccccctgattcctgttcccgtg  
ggggcagcagcctccttctcggcgccccccaatcccattcccggcctggaccccagagcgtggt  
tgccaacagtgacctcttcccagccccgcctcagatcccatctcggccagttcggatcccc  
cagggattccccagggagtgccagcagaagacccccctgctgcgccagccggccccaccatt  
atccgcccagccgagccatccctgctcgacTA GGCCTGTCAGGCCAAGCTTCCATCGATAG  
ACATGATAAGATAACATTGATGAGTTTGGACAAACCACAACAAGAATG

START, STOP, Mutated codon

PCR primers for insertion via in-fusion reaction into Sleeping Beauty pSB-tet-Bla plasmid :

Dynamin\_01\_F ACCCTCGAAAGGCCTCTGAGGCCACCatgggcaaccgcgggatg  
Dynamin\_01\_R ATGGAAGCTTGGCCTGACAGGCCCTAGTCGAGCAGGGATGGCTCGG